Skip to content
Linkedin
RLS logo_header
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Targeted Therapy
    • Thyroid Cancer
    • Uveal Melanoma
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Targeted Therapy
    • Thyroid Cancer
    • Uveal Melanoma
Linkedin

First patient dosed in DESTINY-Endometrial01 Ph 3 Trial of ENHERTU® Initiated as 1L Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer

June 17, 2025

First patient dosed with Debio 1562M in Ph 1/2 trial for AML patients

June 17, 2025

First Patient dosed in Ph 1 Trial of Padeliporfin VTP in Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma (PDAC)

June 17, 2025

First patient dosed in Ph 1/2I study of MT-4561 in patients with advanced solid tumors

June 17, 2025

First Patient Dosed in Registrational Study of Irpagratinib for HCC

June 17, 2025

FDA Removes Partial Clinical Hold from Ph 3 Trial of IFx-2.0 in Advanced or Metastatic Merkel Cell Carcinoma

June 11, 2025

First Patient dosed in Ph 1 ‘HEAT’ Trial of 177Lu-RAD202 for Treatment of Advanced HER2-Positive Solid Tumors

June 10, 2025

Enrollment Completed in Ph 2a Trial of HT-6184 for MDS

June 10, 2025

Dose escalation completed in IAM1363-01 Ph 1/1b trial of IAM1363 in patients with HER2-altered cancers & brain mets / HER2 TKD mutation / HER2-amplified NSCLC

June 10, 2025

Ph 1/2 trial of AVZO-1418 initiated in patients with advanced solid tumors

June 10, 2025

Ph 1/2 trial of AVZO-023 initiated in patients with advanced or metastatic HR+/HER2- breast cancer and select other advanced solid tumors

June 10, 2025

First Patient Enrolled in New Ph 2 Clinical Trial Protocol of Stenoparib in Advanced Ovarian Cancer

June 3, 2025

First Patient dosed in Ph 1b/2 Combination Study of Decoy20 with Tislelizumab

June 3, 2025

Ph 1b Trial Of Nectin-4-Targeting Aky-1189 Initiated Across Multiple Tumor Types

June 3, 2025

First Patient Dosed with CER-1236 in Ph 1 Clinical Trial for AML

June 3, 2025

First Patient Dosed in TNG456 Ph 1/2 Trial in Patients With MTAP-deleted GBM and Other Solid Tumors

May 27, 2025

Monotherapy and combo arms of BBI-355 in POTENTIATE trial to be discontinued; BBI-355 – BBI-825 combo to be investigated

May 27, 2025

IDeate-Esophageal01 Ph 3 Trial of Ifinatamab Deruxtecan Initiated in Certain Patients With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma

May 21, 2025

Clinical development of belrestotug to be discontinued

May 21, 2025

ADCT-602 trial to be discontinued

May 21, 2025

First Patient dosed in AERIAL Trial of NKG2D CAR-T Therapy LEU011 for Solid Tumors

May 21, 2025

Successful End of Ph 2 Meeting with US FDA on Ph 3 Registrational Study Design for PT-112 in Patients with Metastatic CRPC Announced

May 21, 2025

GTB-3650 Ph 1 Trial Advanced to Cohort 2 Following Successful Initial Human Dosing and Evidence of Early Immune Activation Signals

May 21, 2025

Ph 2 Trial evaluating the efficacy and safety of Lutetium (177Lu) rhPSMA-10.1 Injection initiated in metastatic CRPC

May 13, 2025

First Patient Dosed in STARt-002 Trial of Invikafusp Alfa in Combination with Trodelvy® in Metastatic Breast Cancer

May 13, 2025
Page1 Page2 Page3 … Page23

Onco-This-Week

  • Business News
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Conference Coverage

About Us

Sign up for OTW

Linkedin

Disclaimer: The OTW team takes care to share authentic information. In case of any discrepancies please write to newsletter@onco-this-week.com. Our website is an aggregator for open-source oncology news. The information on our website is provided without any representations or warranties. OTW is part of RLS Consultants, a global consulting and training firm focusing exclusively on the healthcare and life sciences industries. RLS is a leading provider of opportunity assessment services, utilizing its comprehensive expertise in strategic market research, forecasting, and modeling, as well as pricing and market access to facilitate commercial assessments. RLS does not have any influence on any news reported on OTW. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of RLS. The content on our website is intended strictly for news and information purposes only and should not be treated as a substitute for medical advice, diagnosis, or treatment. News shared on OTW should not be utilized in real-world analytic products as they are based only on limited and dated open-source information.